Open in interactive viewer → charts, metric popovers & call review

CytoSorbents' $43,000 Lean Quarter

A micro-cap finally stops burning cash — by cutting the sales force that was supposed to grow it, while the De Novo filing slips to 'early 2027' yet again
CTSO · Earnings Call · 2026-11-12

Breakeven, With an Asterisk

On November 12, CytoSorbents (market cap ~$17M) reported its third quarter of 2026 and delivered something it has not delivered in years: a positive number where the cash-burn figure usually sits. As CEO Phillip Chan put it, “We generated approximately $43,000 of positive operating cash flow on that basis.” — Phillip Chan, Chief Executive Officer · 2026-11-12 That "basis" is doing a lot of work — it excludes restructuring-related payments — but the milestone is real enough that management led with it. The mechanics are genuinely cleaner than the headline. Product gross margin hit 75%, and CFO Peter Mariani walked the bridge explicitly: “Product gross margin was 75%, up approximately 2 points from 73% in the second quarter and 5 points from 70% a year ago.” — Peter Mariani, Chief Financial Officer · 2026-11-12 Operating expenses fell 11% year-over-year, the adjusted EBITDA loss narrowed to roughly $300,000, and inventory was drawn down. These are the fingerprints of cost controls and better manufacturing yield rather than demand. That is the tell. The breakeven was engineered from the cost line, not earned from the top line. Gross margin stood at 73.2% in the most recent filing and has now pushed into the mid-70s on the call, but total revenue has been stuck near $10M a quarter since 2021. You can only cut your way to breakeven once.

The Cost-Cut That Cut Growth

Here is where the report earns its tension. The quarter's worst number belongs to Germany — the company's largest direct market, roughly a quarter of sales — and management was unusually candid about why it is shrinking:

Germany, representing the remaining 24%, declined approximately 20%-21% year-over-year, principally because we reduced our sales force and territory coverage during restructuring, not because we believe the market opportunity has disappeared.

Phillip Chan, Chief Executive Officer · 2026-11-12
This is not new information so much as a confession that has been dawning for several quarters. Back in March, Chan framed Germany as a slow repair: “we expect to see incremental improvement over time. Now it's not going to happen suddenly as there's still a lot of work to do.” — Phillip Chan, Chief Executive Officer · 2026-03-25 By May he was promising to get the country “beyond treading water and staying even to actually returning to growth.” — Phillip Chan, Chief Executive Officer · 2026-05-13 Now, three calls on, the market is down 20% and the fix is to re-hire the reps they cut — two already added, more planned into early 2027. The company optimized its P&L by starving the very channel that generates profitable growth. The offsetting channels are the real bright spot: distributor and strategic partner sales rose 18% year-over-year, and direct international sales outside Germany grew 4%, together 76% of the quarter. A leaner company is riding international distributors while it rebuilds its own feet on the street.

The DrugSorb Treadmill

The second, third and fourth "value drivers" all lean on the U.S. regulatory clock, which has a habit of running slower than promised. The lead program, DrugSorb-ATR, is now targeting a new De Novo submission for ticagrelor (BRILINTA) in early 2027 — a date that has migrated more than once. The pattern is visible in the prior calls; in March, Chan was already explaining a slip: “We know that we had talked about trying to submit at the end of March. But I think that we think it's more prudent, rather than to rush it, to try to drive more certainty in the process so that we don't get surprised like we were last year.” — Phillip Chan, Chief Executive Officer · 2026-03-25 Six months later the submission is not in hand but pushed a further year out, and a new animal study has been bolted on to generate mechanistic data for the probable risk-versus-benefit calculus that governs De Novo approval. Management defends the delay as diligence, and there is a real evidentiary upgrade: an independent patient-matched analysis of 587 urgent bypass patients reportedly showed a 37% relative reduction in severe BARC-4 bleeding, a number-needed-to-treat of roughly eight, and the total treated population behind the dossier rising fivefold to about 250 patients. But the animal work is not even started in-house. “First of all, obviously, we don't have internal animal facilities. This is reflective of our collaborative efforts with outside institutions.” — Makis Deliargyris, Unknown · 2026-11-12 A company this size is flying the final approach to a U.S. approval with borrowed laboratory capacity and borrowed time.

The Clock That Actually Matters

Strip away the milestones and one number dominates: the balance sheet. Liabilities to assets reached 102%, and effective net cash has sunk to roughly -$12M, against $5.7M of cash on hand at quarter-end. Free cash flow ex-stock-comp was still about -$1M in the prior filing. The stock knows: price-to-revenue has collapsed to 0.7x, and the shares are down 36% in ninety days, sitting about 39% below their August peak. Two hard deadlines sit before year-end, both acknowledged almost in passing: “we are actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year.” — Peter Mariani, Chief Financial Officer · 2026-11-12 Those are the listing requirements that determine whether this story gets to keep being told on a public exchange at all. That is why the call leaned so hard on the "four value drivers" framing — a deliberate hedge against cash flow breakeven being the only thing standing between solvency and not. The fourth lever, HemoDefend BGA, is explicitly being shopped: non-dilutive government funding, licensing, partnerships — anything that monetizes the asset without cash from the core. "Our future is not dependent on any single commercial, regulatory, or strategic outcome," Chan insisted, which is another way of saying every outcome is now uncertain. The honest read: CytoSorbents bought itself breathing room by shrinking, not by growing. The next twelve months hinge on re-hiring Germany back to health while a regulatory process it does not fully control inches toward 2027 — with a balance sheet that has little patience and a listing that has a deadline.